News articles about Hemispherx BioPharma (NYSE:HEB) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hemispherx BioPharma earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 47.2890257722395 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Hemispherx BioPharma (NYSE HEB) traded up 1.1163% during midday trading on Monday, reaching $0.3261. The company had a trading volume of 118,405 shares. The firm has a 50-day moving average of $0.37 and a 200-day moving average of $0.50. The stock’s market cap is $9.51 million. Hemispherx BioPharma has a 12 month low of $0.30 and a 12 month high of $1.28.

Hemispherx BioPharma (NYSE:HEB) last posted its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%. The business had revenue of $0.21 million for the quarter. On average, equities analysts expect that Hemispherx BioPharma will post $0.00 EPS for the current fiscal year.

WARNING: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at

About Hemispherx BioPharma

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Insider Buying and Selling by Quarter for Hemispherx BioPharma (NYSE:HEB)

Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.